US.VTRS · Viatris

{
  "risk": {
    "level": "Elevated",
    "reason": "risk management score >= 5/10",
    "position": {
      "score": 1.1,
      "details": {
        "atrPct": 3.1020408163265305,
        "turnoverUsdM": 139.33842565999998,
        "liquidityPoints": 0.4,
        "volatilityPoints": 0.7
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.VTRS",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 15.6264,
      "strength_details": {
        "ma_score": 2,
        "atr_score": 1,
        "rsi_score": 2,
        "macd_score": 3,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.2,
      "stop_loss_percent": 6.2,
      "take_profit_price": 17.9038,
      "target_multiplier": 1.9,
      "technical_strength": 1.9,
      "take_profit_percent": 7.5
    },
    "positionPoints": 1.1,
    "stopLossPoints": 1.8,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2088815789473684,
    "stopLossPercent": 6.204081632653061,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 64.7,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 55.7,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 9
  },
  "market": {
    "ma20": 16.1545,
    "ma50": 16.1232,
    "close": 16.66,
    "prevClose": 16.96,
    "avgVolume20": 10339383,
    "volumeRatio": 0.81,
    "changePercent": -1.77
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 9,
    "details": {
      "ret_5d": 0.04911838790931977,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 9,
      "vcp_bonus": 0,
      "vol_ratio": 0.8050843525654231,
      "ret_points": 8,
      "vol_points": 0,
      "range_ratio": 1.0731438767767874,
      "volat_points": 0,
      "day_range_pct": 0.030912364945978425,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 1,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 64.7,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 2.2,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 44,
        "contribution": 2.2
      },
      {
        "raw": 13.2,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 66,
        "contribution": 13.2
      },
      {
        "raw": 7.6,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 50.67,
        "contribution": 7.6
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 6.3,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 63,
        "contribution": 6.3
      },
      {
        "raw": 21.4,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 71.33,
        "contribution": 21.4
      },
      {
        "raw": 3,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 30,
        "contribution": 3
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "觀望",
    "result": 55.7,
    "details": [
      "基本面分析總分: 2.2/5分",
      "資金流分析總分: 13.2/20分",
      "市場環境分析總分: 7.6/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 6.3/10分",
      "技術信號分析總分: 21.4/30分",
      "情緒分析: 3/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 2.2,
      "資金流": 13.2,
      "市場環境": 7.6,
      "情緒分析": 3,
      "技術信號": 21.4,
      "風險管理": 6.3
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 7,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "較差",
        "items": {
          "pbPoints": 0.5,
          "pePoints": 0,
          "epsPoints": 0,
          "roePoints": 0,
          "debtPoints": 0.4,
          "marginPoints": 0,
          "turnoverUsdM": 139.33842565999998,
          "volumePoints": 0.5,
          "revenuePoints": 0,
          "dividendPoints": 0.4,
          "marketCapPoints": 0.4
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "一般",
        "items": {
          "cmfPoints": 0.8,
          "mfiPoints": 2.4,
          "obvPoints": 4,
          "vwapPoints": 4,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.VTRS",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 2.4,
            "details": {
              "source": "twelvedata+fred",
              "vixClose": 16.13
            }
          },
          "trend": {
            "score": 2.4,
            "details": {
              "qqq": {
                "ma20": 720.20150485,
                "ma50": 712.61520144,
                "name": "QQQ",
                "close": 711.44,
                "points": 0.4
              },
              "spy": {
                "ma20": 741.6025084,
                "ma50": 739.6414025000001,
                "name": "SPY",
                "close": 745.40002,
                "points": 2
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 3.1020408163265305,
          "atrPoints": 2,
          "cciPoints": 0.8,
          "vixPoints": 2.4,
          "marketTrendPoints": 2.4
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 3,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 7,
              "negativeHits": 0,
              "positiveHits": 1,
              "sentimentScoreRaw": 0.3
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 140818583,
                "url": "https://finnhub.io/api/news?id=faac0612e5716f2b53e9b7b9d846e0387b0426f3ae1660a9ee69596866fb5d24",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Viatris Inc. recently reported positive Phase 3 results in Japan for VR-205 (Nefecon), an IgA nephropathy treatment, and entered an amended ¥40,000,000,000 senior unsecured term loan agreement with Mizuho Bank to refinance existing debt and support general corporate purposes. The successful VR-205 trial targets a serious kidney disease with high incidence and limited disease-modifying therapies in Japan, positioning Viatris within a clinically important niche of specialty nephrology. We’ll...",
                "category": "company",
                "datetime": 1783328946,
                "headline": "Should Viatris’ Japan IgA Nephropathy Win and New Loan Shape VTRS Investors’ Next Move?"
              },
              {
                "id": 140815821,
                "url": "https://finnhub.io/api/news?id=610db3331ff00641560bf390ae3fbedccd2c12626bb2733f29ec934988e20348",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Viatris Inc. (NASDAQ:VTRS) is one of the Top 10 Extreme Value Stocks To Buy Now. On July 1, Viatris Inc. (NASDAQ:VTRS) entered into a loan agreement with a group of lenders led by Mizuho Bank. The company secured a ¥40 billion senior unsecured term loan. This will support general business purposes and also refinance an […]",
                "category": "company",
                "datetime": 1783291712,
                "headline": "Viatris (VTRS) Secures Loan Amid Positive Phase 3 Results"
              },
              {
                "id": 140813370,
                "url": "https://finnhub.io/api/news?id=7be707864b28e55a13b967a55b198184f4d4247949396684a27340973787013e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Viatris Inc. (NASDAQ:VTRS) is one of the 10 Most Undervalued NASDAQ Stocks to Buy Right Now. On June 29, Viatris announced positive top-line results from a Phase 3 clinical trial of VR-205 (targeted-release budesonide) in Japanese adults with primary immunoglobulin A nephropathy (IgAN). The study met its primary endpoint, demonstrating a statistically significant 33.75% reduction […]",
                "category": "company",
                "datetime": 1783256653,
                "headline": "Viatris (VTRS): Most Undervalued NASDAQ Stocks to Buy Right Now"
              },
              {
                "id": 140793217,
                "url": "https://finnhub.io/api/news?id=19702475956c2f0e44407ebd7e502e43b82b80ae6c83d80cbe2a1fdd7950a0de",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Does Viatris (VTRS) have what it takes to be a top stock pick for momentum investors? Let's find out.",
                "category": "company",
                "datetime": 1783008003,
                "headline": "Viatris (VTRS) is a Great Momentum Stock: Should You Buy?"
              },
              {
                "id": 140704361,
                "url": "https://finnhub.io/api/news?id=b0b5341d803cbe8a4216da13a504d4cf7f8b7a6282ec12ec2818aa6d37f8413e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "VTRS vs. DHR: Which Stock Is the Better Value Option?",
                "category": "company",
                "datetime": 1782229205,
                "headline": "VTRS vs. DHR: Which Stock Is the Better Value Option?"
              },
              {
                "id": 140702838,
                "url": "https://finnhub.io/api/news?id=d92a2bba43cd607e76950935c9c1b2c67720c6dfafda9cacb291d5b7e8b0a143",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.",
                "category": "company",
                "datetime": 1782222004,
                "headline": "Are Investors Undervaluing Viatris (VTRS) Right Now?"
              },
              {
                "id": 140633984,
                "url": "https://finnhub.io/api/news?id=fdf346965e944bc51f98425a0064558ece2ae601dc630a6a5a4e60fd1c15a679",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "What Viatris (VTRS) offers investors today Viatris (VTRS) has been drawing attention from investors after a strong total return over the past year, prompting fresh interest in how its current fundamentals line up with the stock price. The company reports annual revenue of US$14.56b and a reported net loss of US$296.5 million, alongside a value score of 5 and an intrinsic discount estimate of 66.78% relative to one assessment of fair value. See our latest analysis for Viatris. At a share price...",
                "category": "company",
                "datetime": 1781467599,
                "headline": "Viatris (VTRS) Stock And The 58% Undervaluation Debate After A Strong Year Of Returns"
              }
            ],
            "raw_source": [
              {
                "id": 140832866,
                "url": "https://finnhub.io/api/news?id=cab4113429911de971a850c6643e196f8c2937ce65e17b8eb11e2d422699e893",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Healthcare has been an unloved corner of the market in 2026, but that neglect has created a rare setup: quality names trading in single-digit and low-double-digit territory while still throwing off cash, growing earnings, and reaffirming guidance. For retail investors scanning for value, the sub-$30 shelf in healthcare currently offers exposure to a pending strategic ... 3 Dirt Cheap Healthcare Shares Under $30 to Buy Right Now",
                "category": "company",
                "datetime": 1783444791,
                "headline": "3 Dirt Cheap Healthcare Shares Under $30 to Buy Right Now"
              },
              {
                "id": 140818583,
                "url": "https://finnhub.io/api/news?id=faac0612e5716f2b53e9b7b9d846e0387b0426f3ae1660a9ee69596866fb5d24",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Viatris Inc. recently reported positive Phase 3 results in Japan for VR-205 (Nefecon), an IgA nephropathy treatment, and entered an amended ¥40,000,000,000 senior unsecured term loan agreement with Mizuho Bank to refinance existing debt and support general corporate purposes. The successful VR-205 trial targets a serious kidney disease with high incidence and limited disease-modifying therapies in Japan, positioning Viatris within a clinically important niche of specialty nephrology. We’ll...",
                "category": "company",
                "datetime": 1783328946,
                "headline": "Should Viatris’ Japan IgA Nephropathy Win and New Loan Shape VTRS Investors’ Next Move?"
              },
              {
                "id": 140815821,
                "url": "https://finnhub.io/api/news?id=610db3331ff00641560bf390ae3fbedccd2c12626bb2733f29ec934988e20348",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Viatris Inc. (NASDAQ:VTRS) is one of the Top 10 Extreme Value Stocks To Buy Now. On July 1, Viatris Inc. (NASDAQ:VTRS) entered into a loan agreement with a group of lenders led by Mizuho Bank. The company secured a ¥40 billion senior unsecured term loan. This will support general business purposes and also refinance an […]",
                "category": "company",
                "datetime": 1783291712,
                "headline": "Viatris (VTRS) Secures Loan Amid Positive Phase 3 Results"
              },
              {
                "id": 140813370,
                "url": "https://finnhub.io/api/news?id=7be707864b28e55a13b967a55b198184f4d4247949396684a27340973787013e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Viatris Inc. (NASDAQ:VTRS) is one of the 10 Most Undervalued NASDAQ Stocks to Buy Right Now. On June 29, Viatris announced positive top-line results from a Phase 3 clinical trial of VR-205 (targeted-release budesonide) in Japanese adults with primary immunoglobulin A nephropathy (IgAN). The study met its primary endpoint, demonstrating a statistically significant 33.75% reduction […]",
                "category": "company",
                "datetime": 1783256653,
                "headline": "Viatris (VTRS): Most Undervalued NASDAQ Stocks to Buy Right Now"
              },
              {
                "id": 140793217,
                "url": "https://finnhub.io/api/news?id=19702475956c2f0e44407ebd7e502e43b82b80ae6c83d80cbe2a1fdd7950a0de",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Does Viatris (VTRS) have what it takes to be a top stock pick for momentum investors? Let's find out.",
                "category": "company",
                "datetime": 1783008003,
                "headline": "Viatris (VTRS) is a Great Momentum Stock: Should You Buy?"
              },
              {
                "id": 140778927,
                "url": "https://finnhub.io/api/news?id=43a21cb0ced81a94cb20a2ab4b974b4cd0c7c93d6aba90a991a99250f77f6e97",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it will report second-quarter 2026 financial results on Thursday, August 6, 2026. Company executives will host a conference call and live webcast at 8:30 a.m. ET on the same date to discuss the results.",
                "category": "company",
                "datetime": 1782903540,
                "headline": "Viatris to Report Second-Quarter 2026 Financial Results on August 6, 2026"
              },
              {
                "id": 140773043,
                "url": "https://finnhub.io/api/news?id=d350c05ec0fc274e8c6499638c2440b7207f472c50874423fcd02ded7ca7fed2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "TBPH falls after agreeing to a $929 million all-cash acquisition by Zymeworks, following a strategic review triggered by its failed ampreloxetine program.",
                "category": "company",
                "datetime": 1782824040,
                "headline": "Theravance Stock Down 3% After Zymeworks Announces Buyout"
              },
              {
                "id": 140760985,
                "url": "https://finnhub.io/api/news?id=3dd1ff9ee83363090b37f246de1973cd2c39f143d5ba8daa89c35977eb3ae750",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced positive top-line results from a Phase 3 clinical trial evaluating the efficacy and safety of VR-205 (targeted-release budesonide formulation) (Nefecon®) in Japanese adult patients with primary immunoglobulin A nephropathy (IgAN) at risk of developing end-stage renal disease.",
                "category": "company",
                "datetime": 1782730740,
                "headline": "Viatris Announces Positive Top-Line Results from Phase 3 Study of VR-205 in Japanese Adults with Primary Immunoglobulin A Nephropathy"
              },
              {
                "id": 140762016,
                "url": "https://finnhub.io/api/news?id=d3b3f38e1856ec9fb1e6eead6c48b34a2780e550faf72e1a33c1d2c1851edf69",
                "image": "https://cdn.benzinga.com/files/images/story/2026/06/29/Healthcare-stocks.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "VTRS",
                "summary": "Investors turn to dividend-yielding stocks in turbulent markets. Benzinga offers latest analyst ratings for high-yielding stocks, including accuracy rates.",
                "category": "company",
                "datetime": 1782719168,
                "headline": "Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields"
              },
              {
                "id": 140764538,
                "url": "https://finnhub.io/api/news?id=f5769a4d0d7ffd22129a63359db792316d4470e59375f3de16f0da3ecca1f1fd",
                "image": "",
                "source": "Benzinga",
                "related": "VTRS",
                "summary": "VR-205 Met Primary Endpoint and Key Secondary Endpoints and Was Well ToleratedVR-205 Efficacy and Safety Profile in Japanese Patients Was Consistent with the Profile Observed in Global Studies Japanese New Drug",
                "category": "company",
                "datetime": 1782716656,
                "headline": "Viatris’ VR‑205 Phase 3 Trial in Japan Met Primary and Key Secondary Endpoints; Safety Profile Aligned With Global Studies, NDA Filing Planned by End‑2026"
              },
              {
                "id": 140704361,
                "url": "https://finnhub.io/api/news?id=b0b5341d803cbe8a4216da13a504d4cf7f8b7a6282ec12ec2818aa6d37f8413e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "VTRS vs. DHR: Which Stock Is the Better Value Option?",
                "category": "company",
                "datetime": 1782229205,
                "headline": "VTRS vs. DHR: Which Stock Is the Better Value Option?"
              },
              {
                "id": 140702838,
                "url": "https://finnhub.io/api/news?id=d92a2bba43cd607e76950935c9c1b2c67720c6dfafda9cacb291d5b7e8b0a143",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.",
                "category": "company",
                "datetime": 1782222004,
                "headline": "Are Investors Undervaluing Viatris (VTRS) Right Now?"
              },
              {
                "id": 140703228,
                "url": "https://finnhub.io/api/news?id=8e79c669503d11407141d135d3ecf2d2ed9737814b31e80a39f5c9b0a2d97468",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2220570668/image_2220570668.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "VTRS",
                "summary": "Viatris Inc. hits a 52-week high, driven by a strong late-stage pipeline, but shares corrected on Effexor sales decline. Click for this VTRS update.",
                "category": "company",
                "datetime": 1782219355,
                "headline": "Viatris Soared 54%: Time To Be More Careful (Rating Downgrade)"
              },
              {
                "id": 140673224,
                "url": "https://finnhub.io/api/news?id=c7d2ba62a8e457ce66571b22ca879fc56fe8f622e3b6cb1ffb5a2c54155fcb1f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Viatris has outperformed its industry peers over the past year, and Wall Street appears optimistic about the stock.",
                "category": "company",
                "datetime": 1781875941,
                "headline": "How Is Viatris’ Stock Performance Compared to Other Healthcare Stocks?"
              },
              {
                "id": 140666619,
                "url": "https://finnhub.io/api/news?id=6ae8bcbd6b142658ab07f31142a28adccc3d1c6fa67cbde90455bc2da5f1f8dc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "The US Food and Drug Administration said Thursday it is requesting updates to prescribing informatio",
                "category": "company",
                "datetime": 1781819791,
                "headline": "FDA Seeks Updated Labeling for Testosterone Therapies"
              },
              {
                "id": 140645127,
                "url": "https://finnhub.io/api/news?id=01e1a06b0fd3a9ea4ccb812898a15ef08e84b56a5e7b4148509d4b390323a629",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.",
                "category": "company",
                "datetime": 1781617984,
                "headline": "1 Cash-Producing Stock with Exciting Potential and 2 Facing Headwinds"
              },
              {
                "id": 140644640,
                "url": "https://finnhub.io/api/news?id=af3907ec873e77f50db6a38d9f8bb606a49cd09990945cdeae3df412090fe3a0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Viatris Inc. (Nasdaq: VTRS) has been recognized as one of the 2026 Best Workplaces™ in Canada by Great Place to Work®. This recognition highlights Viatris' commitment to fostering a culture where colleagues feel valued, engaged, and empowered to do meaningful work while making a positive impact on patients and communities.",
                "category": "company",
                "datetime": 1781607540,
                "headline": "Viatris Recognized as One of the 2026 Best Workplaces™ in Canada"
              },
              {
                "id": 140633984,
                "url": "https://finnhub.io/api/news?id=fdf346965e944bc51f98425a0064558ece2ae601dc630a6a5a4e60fd1c15a679",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "What Viatris (VTRS) offers investors today Viatris (VTRS) has been drawing attention from investors after a strong total return over the past year, prompting fresh interest in how its current fundamentals line up with the stock price. The company reports annual revenue of US$14.56b and a reported net loss of US$296.5 million, alongside a value score of 5 and an intrinsic discount estimate of 66.78% relative to one assessment of fair value. See our latest analysis for Viatris. At a share price...",
                "category": "company",
                "datetime": 1781467599,
                "headline": "Viatris (VTRS) Stock And The 58% Undervaluation Debate After A Strong Year Of Returns"
              },
              {
                "id": 140633631,
                "url": "https://finnhub.io/api/news?id=85dea798eae9b2aa5ba6fe1d888c2339842dd4f02b3a2222b4214ac8bd176b00",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Viatris (NasdaqGS:VTRS) has completed a significant euro denominated fixed income offering through the issuance of senior unsecured notes. The transaction raises new capital for the company and introduces additional euro currency debt into its balance sheet. The offering follows a period of insider selling and debate around the company’s growth potential. Viatris, a global pharmaceutical company, operates across branded, generic, and biosimilar medicines, as well as over the counter...",
                "category": "company",
                "datetime": 1781460324,
                "headline": "Viatris Euro Debt Raise Reshapes Capital Structure And Valuation Story"
              },
              {
                "id": 140607291,
                "url": "https://finnhub.io/api/news?id=d5673e1ac2b4f8e1fc4bf654dc13090df2b5f5463bf3cf4e2b04066947c31053",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "One company posts rapid revenue growth but remains unprofitable, while the other boasts global scale and steady cash flow. See how their fundamentals stack up.",
                "category": "company",
                "datetime": 1781186755,
                "headline": "Lexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026?"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 7,
            "negative_hits": 0,
            "positive_hits": 1,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0.3,
            "source_article_count": 20,
            "discarded_article_count": 13
          },
          "sentimentPoints": 3
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 21.4,
        "grade": "良好",
        "items": {
          "bbPoints": 3,
          "adxPoints": 3,
          "sarPoints": 2.4000000000000004,
          "vcpPoints": 0.9,
          "macdPoints": 4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 0.9,
            "vcp_reason": "站上MA50；升放量(近10日3日)；Ready=N；Confirm=N",
            "vcp_metrics": {
              "up_days": 7,
              "vol_ref": 10120870,
              "down_days": 2,
              "vcp_ready": false,
              "above_ma50": true,
              "avg_vol_10": 10246510,
              "avg_vol_20": 10388540,
              "avg_vol_30": 10120870,
              "range_pct_10": 0.11704681872749106,
              "range_pct_20": 0.13385354141656675,
              "range_pct_30": 0.13385354141656675,
              "up_expand_ok": true,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": false,
              "down_shrink_ok": false,
              "up_expand_days": 3,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 1.012413952555462,
              "dist_to_20d_high": 0.029702970297029792,
              "down_shrink_days": 1,
              "breakout_level_20d": 17.17,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.8744394618834078
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": false
          },
          "kdjAdxPoints": 0.5,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 2.4,
          "shortRsiPoints": 1,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0.6,
          "volumePointsTechnical": 0.8
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "一般",
        "items": {
          "position": {
            "score": 1.1,
            "details": {
              "atrPct": 3.1020408163265305,
              "turnoverUsdM": 139.33842565999998,
              "liquidityPoints": 0.4,
              "volatilityPoints": 0.7
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.VTRS",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 15.6264,
            "strength_details": {
              "ma_score": 2,
              "atr_score": 1,
              "rsi_score": 2,
              "macd_score": 3,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.2,
            "stop_loss_percent": 6.2,
            "take_profit_price": 17.9038,
            "target_multiplier": 1.9,
            "technical_strength": 1.9,
            "take_profit_percent": 7.5
          },
          "positionPoints": 1.1,
          "stopLossPoints": 1.8,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2088815789473684,
          "stopLossPercent": 6.204081632653061,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 92.86,
    "atr": {
      "atr": 0.5168,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 4,
      "atr_pct": 3.1
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "超買或超賣風險",
      "score": 2,
      "value": 106.89
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "派發",
      "score": 2,
      "value": -0.0733
    },
    "kdj": {
      "d": 76.58,
      "j": 76.32,
      "k": 76.49,
      "rule": "Cursor_18.24 K/D cross",
      "score": 0,
      "signal": "死叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "平衡",
      "score": 6,
      "value": 59.89
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 10,
      "trend": "強流入",
      "value": 120011749,
      "recentSlope": 3712124.9,
      "previousSlope": -1006830
    },
    "rsi": 58.96,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 8,
      "trend": "上升",
      "value": 15.183,
      "position": "SAR喺價下",
      "distancePct": 8.87,
      "previousTrend": "上升"
    },
    "ma50": 16.1232,
    "macd": {
      "macd": 0.19666252032229892,
      "trend": "強烈看漲",
      "signal": 0.10518028123973484,
      "histogram": 0.09148223908256407
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 10,
      "value": 16.1171,
      "position": "連續5日>VWAP",
      "consecutiveAbove": 5
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "無力",
      "ratio": 0.81,
      "score": 4,
      "avgVolume": 10339383,
      "currentVolume": 8363651
    },
    "derived": {
      "ma20": 16.1545,
      "ma50": 16.1232,
      "prevClose": 16.96,
      "avgVolume10": 10201775,
      "avgVolume20": 10339383,
      "changePercent": -1.77,
      "avgVolumeForScore": 10339383
    },
    "ma_cross": {
      "ma20": 16.1545,
      "ma50": 16.1232,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "接近",
      "score": 6,
      "prevMa20": 16.118,
      "prevMa50": 16.0818,
      "spreadPct": 0.19,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 15.298,
      "upper": 17.011,
      "position": "上半部"
    },
    "rsi_short": 62.43,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.81
    }
  }
}

{
  "close": 16.66,
  "volume": 8363651,
  "changePercent": -1.77
}